P81425
Gene name |
DPP4 (CD26) |
Protein name |
Dipeptidyl peptidase 4 |
Names |
|
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:281122 |
EC number |
3.4.14.5: Dipeptidyl-peptidases and tripeptidyl-peptidases |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for P81425
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-P81425-F1 | Predicted | AlphaFoldDB |
69 variants for P81425
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs455301580 | 2 | K>E | No | EVA | |
| rs432643545 | 22 | T>P | No | EVA | |
| rs478133742 | 33 | D>E | No | EVA | |
| rs438730618 | 34 | A>P | No | EVA | |
| rs438730618 | 34 | A>S | No | EVA | |
| rs463628661 | 36 | T>I | No | EVA | |
| rs482021416 | 37 | D>A | No | EVA | |
| rs449017897 | 40 | R>S | No | EVA | |
| rs467265946 | 41 | T>A | No | EVA | |
| rs446376383 | 45 | A>D | No | EVA | |
| rs451140566 | 46 | D>E | No | EVA | |
| rs432671158 | 46 | D>H | No | EVA | |
| rs469669742 | 49 | K>* | No | EVA | |
| rs436563770 | 51 | T>P | No | EVA | |
| rs455143146 | 52 | F>L | No | EVA | |
| rs434096433 | 54 | M>R | No | EVA | |
| rs441660945 | 75 | I>S | No | EVA | |
| rs460809300 | 87 | I>T | No | EVA | |
| rs469431645 | 113 | I>L | No | EVA | |
| rs440398913 | 122 | Q>P | No | EVA | |
| rs1117179225 | 137 | N>K | No | EVA | |
| rs440135571 | 169 | N>S | No | EVA | |
| rs378991725 | 199 | D>N | No | EVA | |
| rs3423132401 | 251 | V>M | No | EVA | |
| rs448265489 | 261 | V>L | No | EVA | |
| rs434585909 | 265 | I>T | No | EVA | |
| rs719669768 | 277 | P>L | No | EVA | |
| rs471811811 | 353 | V>G | No | EVA | |
| rs476761672 | 398 | K>I | No | EVA | |
| rs451762861 | 404 | I>S | No | EVA | |
| rs434688676 | 454 | Q>L | No | EVA | |
| rs467642899 | 455 | Y>C | No | EVA | |
| rs469517618 | 466 | Y>* | No | EVA | |
| rs436372339 | 466 | Y>D | No | EVA | |
| rs450869269 | 470 | R>S | No | EVA | |
| rs456157905 | 489 | E>D | No | EVA | |
| rs437578771 | 490 | L>R | No | EVA | |
| rs464274987 | 491 | R>K | No | EVA | |
| rs433766398 | 498 | D>H | No | EVA | |
| rs466745148 | 504 | Q>K | No | EVA | |
| rs448178928 | 507 | Q>K | No | EVA | |
| rs481410082 | 511 | K>M | No | EVA | |
| rs450027290 | 518 | L>* | No | EVA | |
| rs482791519 | 519 | H>P | No | EVA | |
| rs466585938 | 546 | Y>* | No | EVA | |
| rs452788677 | 550 | C>F | No | EVA | |
| rs464565300 | 560 | L>V | No | EVA | |
| rs438184473 | 575 | A>T | No | EVA | |
| rs457451827 | 584 | Y>D | No | EVA | |
| rs471078296 | 588 | K>N | No | EVA | |
| rs474947026 | 596 | R>I | No | EVA | |
| rs442073753 | 597 | L>V | No | EVA | |
| rs454006325 | 598 | G>* | No | EVA | |
| rs458878683 | 607 | E>D | No | EVA | |
| rs714111111 | 625 | I>V | No | EVA | |
| rs463479050 | 662 | D>G | No | EVA | |
| rs482126407 | 664 | V>L | No | EVA | |
| rs442720772 | 668 | R>S | No | EVA | |
| rs479678726 | 670 | M>R | No | EVA | |
| rs465105298 | 675 | P>L | No | EVA | |
| rs476996051 | 678 | N>S | No | EVA | |
| rs450471387 | 682 | Y>D | No | EVA | |
| rs455206095 | 710 | V>L | No | EVA | |
| rs435046021 | 721 | A>P | No | EVA | |
| rs453653485 | 722 | L>Q | No | EVA | |
| rs471973891 | 723 | V>L | No | EVA | |
| rs439063442 | 727 | V>A | No | EVA | |
| rs452513958 | 733 | W>G | No | EVA | |
| rs470787195 | 741 | I>F | No | EVA |
1 associated diseases with P81425
[MIM: 116300]: Cataract 30, multiple types (CTRCT30)
An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. {ECO:0000269|PubMed:19126778, ECO:0000269|PubMed:26694549, ECO:0000269|PubMed:28450710}. Note=The disease is caused by variants affecting the gene represented in this entry.
Without disease ID
- An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. {ECO:0000269|PubMed:19126778, ECO:0000269|PubMed:26694549, ECO:0000269|PubMed:28450710}. Note=The disease is caused by variants affecting the gene represented in this entry.
7 regional properties for P81425
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | C2 domain | 89 - 211 | IPR000008-1 |
| domain | C2 domain | 251 - 384 | IPR000008-2 |
| domain | Synaptotagmin | 255 - 270 | IPR001565-1 |
| domain | Synaptotagmin | 270 - 283 | IPR001565-2 |
| domain | Synaptotagmin | 327 - 342 | IPR001565-3 |
| domain | Synaptotagmin | 347 - 357 | IPR001565-4 |
| domain | Rabphilin/Doc2, first C2 domain | 90 - 213 | IPR047022 |
Functions
| Description | ||
|---|---|---|
| EC Number | 3.4.14.5 | Dipeptidyl-peptidases and tripeptidyl-peptidases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
10 GO annotations of cellular component
| Name | Definition |
|---|---|
| apical plasma membrane | The region of the plasma membrane located at the apical end of the cell. |
| cell surface | The external part of the cell wall and/or plasma membrane. |
| endocytic vesicle | A membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance. Endocytic vesicles fuse with early endosomes to deliver the cargo for further sorting. |
| extracellular region | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| intercellular canaliculus | An extremely narrow tubular channel located between adjacent cells. An instance of this is the secretory canaliculi occurring between adjacent parietal cells in the gastric mucosa of vertebrates. |
| lamellipodium | A thin sheetlike process extended by the leading edge of a migrating cell or extending cell process; contains a dense meshwork of actin filaments. |
| lamellipodium membrane | The portion of the plasma membrane surrounding a lamellipodium. |
| membrane raft | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
8 GO annotations of molecular function
| Name | Definition |
|---|---|
| aminopeptidase activity | Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain. |
| chemorepellent activity | Providing the environmental signal that initiates the directed movement of a motile cell or organism towards a lower concentration of that signal. |
| dipeptidyl-peptidase activity | Catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain. |
| protease binding | Binding to a protease or a peptidase. |
| protein homodimerization activity | Binding to an identical protein to form a homodimer. |
| serine-type endopeptidase activity | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine). |
| signaling receptor binding | Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| virus receptor activity | Combining with a virus component and mediating entry of the virus into the cell. |
13 GO annotations of biological process
| Name | Definition |
|---|---|
| behavioral fear response | An acute behavioral change resulting from a perceived external threat. |
| cell adhesion | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. |
| endothelial cell migration | The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| locomotory exploration behavior | The specific movement from place to place of an organism in response to a novel environment. |
| negative regulation of extracellular matrix disassembly | Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix. |
| negative regulation of neutrophil chemotaxis | Any process that decreases the frequency, rate, or extent of neutrophil chemotaxis. Neutrophil chemotaxis is the directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding. |
| positive regulation of cell population proliferation | Any process that activates or increases the rate or extent of cell proliferation. |
| proteolysis | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. |
| psychomotor behavior | The specific behavior of an organism that combines cognitive functions and physical movement. For example, driving a car, throwing a ball, or playing a musical instrument. |
| regulation of cell-cell adhesion mediated by integrin | Any process that modulates the frequency, rate, or extent of cell-cell adhesion mediated by integrin. |
| response to hypoxia | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| T cell activation | The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific. |
| T cell costimulation | The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the T cell receptor to augment T cell activation. |
4 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P81425 | DPP4 | Dipeptidyl peptidase 4 | Bos taurus (Bovine) | PR |
| Q6NXK7 | Dpp10 | Inactive dipeptidyl peptidase 10 | Mus musculus (Mouse) | PR |
| Q10MJ1 | GEP | Probable glutamyl endopeptidase, chloroplastic | Oryza sativa subsp japonica (Rice) | PR |
| Q18253 | dpf-2 | Dipeptidyl peptidase family member 2 | Caenorhabditis elegans | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MKTPWKVLLG | LLAIAALVTV | ITVPVVLLTK | GNDASTDSRR | TYTLADYLKN | TFRMKFYNLR |
| 70 | 80 | 90 | 100 | 110 | 120 |
| WVSDHEYLYK | QENNILLFNA | EYGNSSIFLE | NSTFDEFGHS | INDYSVSPDR | QYILFEYNYV |
| 130 | 140 | 150 | 160 | 170 | 180 |
| KQWRHSYTAS | YDIYDLNKRQ | LITEERIPNN | TQWITWSSVG | HKLAYVWNND | IYVKNEPNSP |
| 190 | 200 | 210 | 220 | 230 | 240 |
| SQRITWTGKK | DVIYNGITDW | VYEEEVFSAY | SALWWSPNST | FLAYAQFNDT | EVPLIEYSFY |
| 250 | 260 | 270 | 280 | 290 | 300 |
| SDESLQYPKT | VKIPYPKAGA | VNPTIKFFVV | NISSLSPNIN | ATSQQIVPPG | SVLIGDHYLC |
| 310 | 320 | 330 | 340 | 350 | 360 |
| DVTWVTEERI | SLQWLRRIQN | YSIMDICDYD | RSTGRWISSV | GRQHIEISTT | GWVGRFRPAE |
| 370 | 380 | 390 | 400 | 410 | 420 |
| PHFTSDGNSF | YKIISNEEGY | KHICHFQTDK | RNCTFITKGA | WEVIGIEALT | SDYLYYISNE |
| 430 | 440 | 450 | 460 | 470 | 480 |
| YKGMPGARNL | YKIQLNDYTK | VTCLSCELNP | DRCQYYSVSF | SQEAKYYQLR | CSGPGLPLYT |
| 490 | 500 | 510 | 520 | 530 | 540 |
| LHNSNNDKEL | RVLENNSDLD | QVLQDVQMPS | KKLDFIHLHG | TKFWYQMILP | PHFDKSKKYP |
| 550 | 560 | 570 | 580 | 590 | 600 |
| LLLEVYAGPC | SQKADAIFRL | NWATYLASTE | NIIVASFDGR | GSGYQGDKIM | HAINRRLGTF |
| 610 | 620 | 630 | 640 | 650 | 660 |
| EVEDQIEATR | QFSKMGFVDD | KRIAIWGWSY | GGYVTSMVLG | AGSGVFKCGI | AVAPVSKWEY |
| 670 | 680 | 690 | 700 | 710 | 720 |
| YDSVYTERYM | GLPTPEDNLD | SYRNSTVMSR | AENFKQVEYL | LIHGTADDNV | HFQQSAQISK |
| 730 | 740 | 750 | 760 | ||
| ALVDAGVDFQ | SMWYTDEDHG | IASSTAHQHI | YTHMSHFLKQ | CFSLL |